Table 1.

Characteristics of patients who underwent a kidney transplant at Centre Hospitalier de l’Université de Montréal between 2008 and 2017 for whom a graft biopsy was available pretransplantation and post-transplantation

CharacteristicsDelayed Graft Function, n=61Immediate Graft Function, n=130
Recipient characteristics
 Age, yr, mean (SD)48 (12)49 (13)
 Sex, women, n (%)17 (28)51 (39)
 Smoker or ex-smoker, n (%)34 (56)63 (48)
 Weight, kg, mean (SD)77 (18)71 (15)
 Height, m, mean (SD)1.70 (0.10)1.69 (0.09)
 Race, n (%)
  White46 (75)96 (74)
  Black6 (10)10 (8)
 Cause of CKD, n (%)
  Glomerular diseases22 (36)51 (39)
  Diabetes9 (15)13 (10)
  Hypertension/vascular5 (8)6 (4)
  Polycystic kidney disease10 (16)30 (23)
  Autoimmune disease3 (5)7 (5)
  Urologic9 (15)14 (11)
  Unknown11 (15)15 (10)
 Diabetes, n (%)14 (23)17 (13)
 First transplantation, n (%)62 (83)131 (90)
 Preemptive transplantation, n (%)5 (8)20 (15)
 Median time on dialysis before transplantation, mo (IQR)45 (18–44)31 (9–54)
 Pretransplant panel-reactive antibodies >0%, n (%)10 (16)17 (13)
 Statin use at transplantation, n (%)24 (39)69 (53)
 ACE inhibitor use at transplantation, n (%)16 (26)67 (52)
Donor characteristics
 Donor type, n (%)
  Living donor4 (7)56 (43)
  Neurologic determination of death43 (70)69 (53)
  Donation after cardiac death14 (23)5 (4)
 Age, yr, mean (SD)47 (15)47 (13)
 Sex, women, n (%)34 (56)65 (50)
 Hypertension, n (%)14 (23)16 (12)
 Diabetes, n (%)5 (8)4 (3)
 Smoker or ex-smoker, n (%)29 (48)46 (35)
 Mean donor creatinine, mg/dl (SD)0.77 (0.38)0.76 (0.25)
 Median number of HLA mismatches (IQR)4 (3–4)4 (3–5)
 Use of hypothermic perfusion machine, n (%)22 (36)71 (55)
Preimplantation biopsy findings
 Median % global glomerulosclerosis (IQR)4 (0–7)3 (1–6)
 Interstitial fibrosis (ci) score, n (%)
  036 (59)95 (73)
  122 (36)31 (24)
  23 (5)4 (3)
  30 (0)0 (0)
 Vascular fibrous intimal thickening (cv) score, n (%)
  036 (59)62 (48)
  112 (20)29 (22)
  211 (18)35 (27)
  32 (3)4 (3)
Peritransplantation events
 Cold ischemic time, h, mean (SD)10 (5)8 (5)
 Warm ischemic time, min, mean (SD)39 (11)38 (10)
 Induction, n (%) thymoglobulin28 (47)27 (21)
Post-transplant biopsy
 Median time to biopsy, d (IQR)106 (21–117)117 (104–129)
 Surveillance biopsy, n (%)54 (89)121 (93)
Rejection before/on surveillance biopsy, n (%)18 (30)23 (18)
 T cell mediated, borderline13 (72)13 (56)
 T cell mediated, Banff grade 1A3 (17)7 (30)
 T cell mediated, Banff grade 2A2 (11)0 (0)
 Antibody mediated0 (0)2 (9)
 Chronic T cell–mediated rejection0 (0)1 (4)
  • IQR, interquartile range; ACE, angiotensin-converting enzyme; ci, Banff score for interstitial fibrosis; cv, Banff score for vascular fibrous intimal thickening.